Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 126 for colorectal

Edit search filters
  1. Regorafenib in Metastatic Colorectal Cancer

    Rochester, MN

  2. MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

    Scottsdale/Phoenix, AZ

  3. A Global, Randomized, Placebo-controlled Phase 3 Study of Fruquintinib in Patients with Refractory Metastatic Colorectal Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  4. Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)

    Rochester, MN

  5. A Study Evaluating the Safety and Effectiveness of Therapies in Patients with Metastatic Colorectal Cancer (INTRINSIC)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

    Jacksonville, FL

  7. MC200404, Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Late-stage Metastatic Colorectal Cancer

    Rochester, MN

  8. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  9. A Study in Second Line Metastatic Colorectal Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  10. Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer